By Dr. Erica Pascal

­The use of inter partes review (IPR) to challenge patents has grown significantly since its initiation in September 2012. In the first four months of IPRs, the USPTO received 97 petitions. In the parallel months of 2014, 578 new petitions were filed. Not surprising: as statistics go for invalidating patents, the IPR process scores high – so much so that the US Patent Trial and Appeal Board (PTAB) has had to defend itself from allegations that it is a “death squad” for patent rights.


Continue Reading ARE IPRs IMPACTING THE PHARMACEUTICAL INDUSTRY?

The EU will soon introduce its new European patent with unitary effect and single Unified Patent Court. To help clients tackle this major change, DLA Piper has launched its Unitary Patent and Unified Patent Court microsite, offering step-by-step guidance on what you need to know and how you need to prepare for the new system – the biggest game-changer in European patent law history.


Continue Reading DLA PIPER LAUNCHES EU UNIFIED PATENT COURT MICROSITE